Medicare Officially Limits Aduhelm Coverage to Clinical Patients

Ever since Medicare proposed to sharply limit the coverage of the controversial Alzheimer’s drug Aduhelm, the agency has been flooded with fiery pleas. Groups representing patients insisted that the federal insurance program pay for the drug. Many Alzheimer’s experts and doctors have warned against broadly considering a treatment with uncertain benefits and serious safety risks. […]

(0)